Aequus Pharmaceuticals (TSE:AQS) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aequus Pharmaceuticals has secured an exclusive deal with Advanced Ophthalmic Innovations to distribute the PAUL® glaucoma drainage device in Canada, a product already approved in over 40 countries. The agreement enhances Aequus’s ophthalmology portfolio and leverages its existing sales infrastructure, aiming for a Canadian launch in Q4. The PAUL® device offers an innovative treatment option for patients with moderate to severe glaucoma, aligning with Aequus’s commitment to improving eyecare.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.